Alpha 2C Adrenergic Receptor drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023
The report also covers products from therapy areas such as Central Nervous System, and Undisclosed which include the indications Schizophrenia, Dementia Associated With Alzheimer’s Disease, and Unspecified. It also reviews key players involved in Alpha 2C Adrenergic Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha 2C Adrenergic Receptor pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and IND/ CTA Filed stages are 1, 1, 1, 2, and 1 respectively.
Alpha 2C Adrenergic Receptor overview
Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.
For a complete picture of Alpha 2C Adrenergic Receptor’s drug pipeline, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#Alpha #Adrenergic #Receptor #drugs #development #Therapy #Areas #Indications #Stages #MoA #RoA #Molecule #Type #Key #Players